Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.87 USD
Change Today -1.10 / -5.80%
Volume 99.8K
LJPC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

la jolla pharmaceutical co (LJPC) Snapshot

Open
$18.81
Previous Close
$18.97
Day High
$19.04
Day Low
$17.64
52 Week High
03/11/15 - $24.89
52 Week Low
05/23/14 - $6.17
Market Cap
272.4M
Average Volume 10 Days
76.9K
EPS TTM
$-2.49
Shares Outstanding
15.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LA JOLLA PHARMACEUTICAL CO (LJPC)

la jolla pharmaceutical co (LJPC) Related Bloomberg News

View More Bloomberg News

la jolla pharmaceutical co (LJPC) Related Businessweek News

No Related Businessweek News Found

la jolla pharmaceutical co (LJPC) Details

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company engages in developing LJPC-501, an angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome; and GCS-100, a galectin-3 inhibitor for the potential treatment of chronic kidney disease. It also develops LJPC-1010 galectin-3 inhibitor for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis; and LJPC-401, a hepcidin for the potential treatment of hemochromatosis and beta thalassemia. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

25 Employees
Last Reported Date: 03/16/15
Founded in 1989

la jolla pharmaceutical co (LJPC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $705.0K
Compensation as of Fiscal Year 2014.

la jolla pharmaceutical co (LJPC) Key Developments

La Jolla Pharmaceutical Co. expected to report Fiscal Year 2014 results on April 17, 2015. This event was calculated by Capital IQ (Created on April 11, 2015).

La Jolla Pharmaceutical Co. expected to report Fiscal Year 2014 results on April 17, 2015. This event was calculated by Capital IQ (Created on April 11, 2015).

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer

La Jolla Pharmaceutical Company announced that Dennis Mulroy will join the company as Chief Financial Officer, effective April 6, 2015. Prior to joining La Jolla, Mr. Mulroy served as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc.

La Jolla Pharmaceutical Co. Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension

La Jolla Pharmaceutical Company announced that it has initiated its ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial, a Phase 3 clinical trial of LJPC-501for the treatment of catecholamine-resistant hypotension (CRH). In February 2015, the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), in which it was agreed that the primary efficacy endpoint for the trial would be increase in blood pressure. CRH is an acute, life-threatening condition in which blood pressure drops to dangerously low levels in patients who respond poorly to current treatments. In accordance with the SPA, the ATHOS 3 trial is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial of LJPC-501 in patients with CRH. The ATHOS 3 trial is designed to enroll approximately 315 patients. Patients will be randomized 1:1 to receive either LJPC-501 plus standard-of-care vasopressors or placebo plus standard-of-care vasopressors. Randomized patients will receive their assigned treatment via continuous IV infusion for up to 7 days. The primary efficacy endpoint of the ATHOS 3 trial is to compare the change in mean arterial pressure between the two groups in the trial. Secondary endpoints include comparison of changes in Sequential Organ Failure Assessment scores and the safety and tolerability of LJPC-501 in patients with CRH. The company has reached agreement with the FDA that an adequately sized Phase 3 trial comprised of 200-300 patients would provide a sufficient safety database to support FDA review and consideration for marketing approval. The prognosis for patients suffering from CRH is very poor, and current treatment options are limited.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $17.87 USD -1.10

LJPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LJPC.
View Industry Companies
 

Industry Analysis

LJPC

Industry Average

Valuation LJPC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit www.ljpc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.